Director/PDMR Shareholding
GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Luke Miels
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
23.331
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
297.818
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Mike Crichton
b)
Position/status
President, International
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
1.100
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
2,014.345
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Nina Mojas
b)
Position/status
President, Global Product Strategy
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
246.181
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Roanne Parry
b)
Position/status
Chief People Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
1.400
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
6,532.657
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
2,999.067
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
2,707.449
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
1,204.461
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Tony Wood
b)
Position/status
Chief Scientific Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
2,558.851
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
169.615
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Kate Thomson
b)
Position/status
PCA of Philip Thomson (President, Global Affairs)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.5904
112.233
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-08
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Elizabeth McKee Anderson
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
41
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Charles Bancroft
b)
Position/status
Senior Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
412
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Dr Hal Barron
b)
Position/status
Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
32
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Dr Anne Beal
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
47
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Dr Harry Dietz
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
45
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Dr Jeannie Lee
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
27
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Dr Vishal Sikka
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5883
136
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-09
f)
Place of the transaction
New York Stock Exchange (XNYS)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFFFFEDEMSEIS
